Fritextsökning
Innehållstyper
-
Seminar program Biotech Forum
Here is the entire seminar program at Biotech Forum September 28-29th
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study...
-
Testar ny behandling av svår PMS
Umeåbolaget Umecrine Mood är halvvägs igenom fas IIa-studie med sin läkemedelskandidat mot premenstruella besvär. Nu letar forskningsbolaget efter en partner ti...
-
We are poor lobbyists
I doubt there has ever been a really well thought out Scandinavian campaign with intentions to really change attitudes among both the public and politicians.
-
DKK 1,3 billion for grand research
Danish Councils for Independent Research, DFF, will grant DKK 1,3 billion during 2009. Now has the application period started.
-
Ytterligare ett stort bakslag för Alzheimerspreparat
Trots alla misslyckanden är intresset mycket stort att hitta ett läkemedel som inte bara lindrar symtomen.
-
New faces in Pronova Biopharma team
The Norwegian company Pronova Biopharma has recently changed the management team structure.
-
Ny design på klinstudie
I ett samarbete mellan FDA, NIH och läkemedelsindustrin utvärderas ett flertal behandlingar i samma studie.
-
Fewer visitors but satisfied exhibitors
Biotech Forum Scanlab attracted fewer visitors than in 2008. Exhibition manager Bo Rasmussen is content, claiming that the exhibitors are very satisfied.
-
New firm based on SLU research
Four researchers at the Swedish University of Agricultural Sciences, SLU, has recently founded a new nanotech company.
-
New CEO to Swedish Tillotts Pharma
The Swiss company Tillotts Pharma's newly established Swedish organisation has appointed a CEO from Bayer Scandinavia.
-
Samarbete med universitet ska gynna Novo
I Combine samarbetar sex svenska universitet för att skapa bättre förståelse kring inflammatoriska sjukdomar. Bolaget ska nu delta i ett projekt för att arbeta ...
-
Höjdpunkter från BIO 2016
Att hälso- och sjukvården håller på att transformeras ordentligt, både av nödvändighet och av att nya teknologier kommer att utmana många delar av traditionell ...
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Baxter bildar njurhubb i Lund
Flyttar över experter från USA som tillsammans med de svenska topparna ska leda det uppdaterade produktområdet inom njurvård.
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
Future drugs from Amaryllis
A Danish research team has discovered possibolities to extract drugs fro Amaryllis.
-
VTT in brief
VTT is a broad science cluster with research within applied materials, chemical and biochemical processes, energy, industrial systems management, information an...
-
Datorn som matchmaker
Datorbaserade modeller kan användas för att förstå interaktioner mellan två läkemedel eller förutsäga biverkningar. - Det blir också möjligt att identifiera pro...
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Recipharm launches into biologics manufacturing
Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.
-
Danish biorefinery can save US billions
The Danish Inbicon biorefinery process could save the US billions on foreign oil, the organization states.
-
Woman deficit in Swedish research
The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.
BREAKING